| |
| |
|
| Insider
Information: |
Squinto Stephen P |
| Relationship: |
Director, 10% Owner |
| City: |
Cheshire |
| State: |
CT |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
2 |
|
| Direct
Shares |
238,160 |
|
|
Indirect Shares
|
6,290,493 |
|
|
| Direct
Value |
$19,437,710 |
|
|
|
Indirect Value
|
$19,013,945 |
|
|
| Total
Shares |
6,528,653 |
|
|
| Total
Value |
$38,451,655 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Alexion Pharmaceuticals Inc |
ALXN |
EVP, Chief Global Ops.... |
2014-10-27 |
106,508 |
2013-10-28 |
104,186 |
Premium* |
|
|
Springworks Therapeutics, Inc. |
SWTX |
Director, 10% Owner |
2022-05-19 |
131,652 |
2022-05-19 |
6,186,307 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
148 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 5 of 6
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| ALXN |
Alexion Pharmaceuticals I... |
EVP & Head of Research & Devel |
• – – |
2008-05-19 |
4 |
AS |
$69.72 |
$2,501,336 |
D/D |
(35,827) |
15,901 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP & Head of R&D |
• – – |
2010-11-03 |
4 |
S |
$70.14 |
$701,400 |
D/D |
(10,000) |
34,873 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP, Research & Development |
• – – |
2012-01-27 |
4 |
S |
$74.41 |
$49,334 |
D/D |
(663) |
77,626 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP, Research & Development |
• – – |
2012-01-30 |
4 |
S |
$74.51 |
$223,828 |
D/D |
(3,004) |
74,662 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP, Research & Development |
• – – |
2012-01-10 |
4 |
S |
$75.00 |
$42,150 |
D/D |
(562) |
78,289 |
0 |
- |
|
| SWTX |
Springworks Therapeutics,... |
Director |
– • • |
2021-04-15 |
4 |
AS |
$75.01 |
$79,291 |
D/D |
(1,057) |
145,160 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP & Head of Research |
• – – |
2007-11-05 |
4 |
AS |
$75.03 |
$2,625,900 |
D/D |
(34,998) |
13,772 |
0 |
- |
|
| SWTX |
Springworks Therapeutics,... |
Director |
– • • |
2021-04-27 |
4 |
AS |
$75.05 |
$15,085 |
D/D |
(201) |
144,959 |
0 |
- |
|
| SWTX |
Springworks Therapeutics,... |
Director |
– • • |
2021-04-14 |
4 |
AS |
$75.08 |
$38,365 |
D/D |
(511) |
146,217 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP & Head of Research & Devel |
• – – |
2008-07-10 |
4 |
S |
$75.75 |
$12,044 |
D/D |
(159) |
15,742 |
0 |
- |
|
| SWTX |
Springworks Therapeutics,... |
Director |
– • • |
2021-04-28 |
4 |
AS |
$76.20 |
$1,465,437 |
D/D |
(19,231) |
125,728 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP, Chief Global Ops. Officer |
• – – |
2013-10-28 |
4 |
OE |
$78.88 |
$3,271,739 |
D/D |
40,037 |
145,223 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP & Head of R&D |
• – – |
2011-01-10 |
4 |
S |
$81.27 |
$22,756 |
D/D |
(280) |
34,593 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP, Research & Development |
• – – |
2012-02-17 |
4 |
S |
$81.27 |
$4,495,938 |
D/D |
(55,260) |
87,662 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP & Head of R&D |
• – – |
2011-01-18 |
4 |
AS |
$82.66 |
$2,919,280 |
D/D |
(34,346) |
34,247 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP & Head of R&D |
• – – |
2011-01-27 |
4 |
S |
$84.70 |
$112,651 |
D/D |
(1,330) |
32,917 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP, Research & Development |
• – – |
2012-06-06 |
4 |
S |
$90.00 |
$4,500,000 |
D/D |
(50,000) |
87,662 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP, Head of R&D |
• – – |
2013-03-08 |
4 |
S |
$91.21 |
$1,827,162 |
D/D |
(20,000) |
108,462 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP, Chief Global Ops. Officer |
• – – |
2014-02-06 |
4 |
OE |
$93.83 |
$356,554 |
D/D |
3,800 |
98,618 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP, Head of R&D |
• – – |
2013-01-29 |
4 |
S |
$94.32 |
$72,343 |
D/D |
(767) |
84,497 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP, Global Ops. Officer |
• – – |
2013-07-01 |
4 |
AS |
$94.34 |
$4,190,622 |
D/D |
(44,125) |
108,462 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP, Research and Development |
• – – |
2011-02-18 |
4 |
S |
$94.42 |
$944,200 |
D/D |
(10,000) |
39,637 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP, Head of R&D |
• – – |
2013-01-28 |
4 |
S |
$94.50 |
$67,568 |
D/D |
(715) |
85,264 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP, Head of R&D |
• – – |
2013-02-04 |
4 |
S |
$95.66 |
$246,081 |
D/D |
(2,572) |
81,925 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
EVP, Global Ops. Officer |
• – – |
2013-04-29 |
4 |
AS |
$98.96 |
$3,612,051 |
D/D |
(36,499) |
108,462 |
0 |
- |
|
148 Records found
|
|
Page 5 of 6 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
